1-6 of 6
Umesh Muchhal
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Igm-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager Demonstrates Potent Efficacy on Myeloma Cells with an Improved Preclinical Safety Profile

Keyu Li, Rui Yun, Min Chai, Poonam Yakkundi, Rodnie Rosete, Gene Li, Liqin Liu, Dean Ng, Paul R. Hinton, Maya F. Kotturi, Angus M. Sinclair, Stephen F. Carroll, Umesh Muchhal, Bruce A. Keyt
Journal: Blood
Blood (2022) 140 (Supplement 1): 6010–6011.
https://doi.org/10.1182/blood-2022-159205
Published: 2022
Journal Articles

Preclinical Characterization of AMG 424, a Novel Humanized T Cell-Recruiting Bispecific Anti-CD3/CD38 Antibody

Christina de Zafra, Mercedesz Balazs, Flordeliza Fajardo, Lingming Liang, Wendy Zhong, Anja Henn, Matthew J. Bernett, Gregory Moore, Umesh Muchhal, Dwight Winters, Brendon Frank, Kevin Cook, Josh Pearson, Murad Melhem, Vladimir Petrovic, Robert J. Pelham, Matthias Friedrich, Hong Tan, Gordon Moody, Jenitte Stevens, John Desjarlais, Angela Coxon, Olivier Nolan-Stevaux
Journal: Blood
Blood (2017) 130 (Supplement 1): 500.
https://doi.org/10.1182/blood.V130.Suppl_1.500.500
Published: 2017
Journal Articles

Tuning T Cell Affinity Improves Efficacy and Safety of Anti-CD38 × Anti-CD3 Bispecific Antibodies in Monkeys - a Potential Therapy for Multiple Myeloma

Gregory L. Moore, PhD, Sung-Hyung Lee, PhD, Suzanne Schubbert, PhD, Yvonne Miranda, MS, Rumana Rashid, PhD, Erik Pong, BS, Sheryl Phung, MS, Emily W. Chan, BS, Hsing Chen, MS, Nancy Endo, BS, Maria C. Ardila, BS, Matthew J. Bernett, PhD, Seung Chu, PhD, Irene W.L. Leung, PhD, Umesh Muchhal, PhD, Christine Bonzon, PhD, David E Szymkowski, PhD, John Desjarlais, PhD
Journal: Blood
Blood (2015) 126 (23): 1798.
https://doi.org/10.1182/blood.V126.23.1798.1798
Published: 2015
Journal Articles

Ratios Of FcγRIIa and FcγRIII Binding Affinities Govern The Efficacy Of PMN-Mediated Cytotoxicity – Implications For Fc-Engineering Approaches Of Therapeutic Antibodies

Stefanie Derer, PhD, Pia Glorius, PhD, Martin Schlaeth, Stefan Lohse, PhD, Umesh Muchhal, Ph.D., John Desjarlais, Andreas Humpe, MD, Thomas Valerius, MD, Matthias Peipp, PhD
Journal: Blood
Blood (2013) 122 (21): 3466.
https://doi.org/10.1182/blood.V122.21.3466.3466
Published: 2013
Journal Articles

Lenalidomide Enhances Multiple Myeloma Cytotoxicity Induced by a Novel Fc Domain-Engineered Anti-HM1.24 Monoclonal Antibody with Augmented NK Cell Degranulation

Sun-Young Kong, MD, PhD, Sabikun Nahar, Xian-Feng Li, Weihua Song, MD, Yiguo Hu, Umesh Muchhal, John Desjarlais, Paul Richardson, M.D., Ph.D., Nikhil C. Munshi, MD, Kenneth C. Anderson, Yu-Tzu Tai, PhD
Journal: Blood
Blood (2010) 116 (21): 4064.
https://doi.org/10.1182/blood.V116.21.4064.4064
Published: 2010
Journal Articles

XmAb®5592 Fc-Engineered Humanized Anti-HM1.24 Monoclonal Antibody Has Potent in Vitro and In Vivo Efficacy against Multiple Myeloma.

Yu-Tzu Tai, Ph.D., Umesh Muchhal, Ph.D., Xian-Feng Li, MS, Sabikun Nahar, B.S., Weihua Song, MD, Holly Horton, Ph.D, Hanh Nguyen, Sher Karki, John Desjarlais, Nikhil C. Munshi, MD, Paul Richardson, M.D., Ph.D., Kenneth C. Anderson, MD
Journal: Blood
Blood (2009) 114 (22): 609.
https://doi.org/10.1182/blood.V114.22.609.609
Published: 2009